=+4Week0481216202428323640444852KSI-3015mgQ20WQ12WQ16WQ12WQ12WQ16WPrimaryEndpointDiseaseActivityAssessmentsDiseaseActivityAssessmentsAflibercept2mgQ8WKSI-301injectionDiseaseActivityAssessmentVisitDiseaseActivityDosingAdjustmentKSI-301individualizedtreatment/shamShaminjectionAfliberceptinjectionClinicaltrials.gov,studyidentifier:NCT04049266AMD:age-relatedmaculardegeneration;Q8W:every8weeks,Q12W:every12weeks;Q16W;every16weeks;Q20W:every20weeks.5••••••Q8W:every8weeks;Q12W:every12weeks;Q16W;every16weeks;Q20W:every20weeks.6N=Numberofparticipantstreated;ThedenominatorforpercentagesisthenumberofparticipantstreatedwithineachtreatmentarmQ8W:every8weeks;Q12W:...
发表评论取消回复